Probiotici e Allergopatie

Diego Peroni

Università di Pisa



FIRENZE 6/9 APRILE 2017 | WWW.SIAAIC2017.ORG

Microbioma, disbiosi e malattia

Probiotici e Allergia

Conclusioni





Transforming Life: A Broad View of the Developmental Origins of Health and Disease Concept from an Ecological Justice Perspective. S. Prescott, Int. J. Environ. Res. Public Health 2016, 13, 1075

The holobiont view of human life underscores that we are assemblages of different species—persistent symbionts—that make up an ecological unit.

The human host and its microbiome (trillions of microbes and their collective genomes) are therefore an ecological community.

In turn, the holobiont operates within its own ecological theater—that is, the often inequitable biotic and abiotic neighborhood.

Transforming Life: A Broad View of the Developmental Origins of Health and Disease Concept from an Ecological Justice Perspective. S. Prescott, Int. J. Environ. Res. Public Health 2016, 13, 1075

Functions of the microbiome include, but are not limited to:

- \checkmark "education" of the immune system,
- ✓ protection against pathogens,
- \checkmark maintenance of barriers to the external environment,
- nutrient production and extraction, increasing bioavailability of dietary phytochemicals, lipid metabolism, provision of short chain fatty acids, production of bioactive metabolites, and
- $\checkmark\,$ detoxification of environmental toxins

Collectively these benefits can be described as **ecosystem** services.

The ISME Journal (2016), $1{-}10$ $\hfill 0$ 2016 International Society for Microbial Ecology All rights reserved 1751-7362/16

www.nature.com/ismej

ORIGINAL ARTICLE

Microbiota network and mathematic microbe mutualism in colostrum and mature milk collected in two different geographic areas: Italy versus Burundi

Lorenzo Drago^{1,2}, Marco Toscano¹, Roberta De Grandi², Enzo Grossi³, Ezio M Padovani⁴ and Diego G Peroni^{5,6}

Bacterial distribution in each type of milk sample:

(a) Italian colostrum;

- (b) Italian mature milk;
- (c) Burundian colostrum;

(d) Burundian mature milk

- Mothers from Burundi and Verona
- Colostrum and mature milk (1 mo.)
- Bacterial DNA extraction and 16S gene sequencing
- The autocontractive map





Colostrum from Italy



The ISME Journal (2016), 1–10 © 2016 International Society for Microbial Ecology All rights reserved 1751-7362/16

lovani⁴

www.nature.com/ismej

ORIGINAL ARTICLE

Microbiota network and mathematic microbe mutualism in colostrum and mature milk collected in two different geographic areas: Italy versus Burundi

Lorenzo Drago^{1,2}, Marco Toscano¹ Roberta De C and Diego G Peroni^{5,6}

> The microbiota of human milk is a dynamic, and complex, ecosystem with different bacterial networks among different populations containing diverse microbial hubs and central nodes, which change during the transition from colostrum to mature milk.

Bacterial distribution in each type of milk sample:

(a) Italian colostrum;

(b) Italian mature milk;

- (c) Burundian colostrum;
- (d) Burundian mature milk

b

The ISME Journal (2016), $1\!-\!10$ © 2016 International Society for Microbial Ecology All rights reserved 1751-7362/16

www.nature.com/ismej

ORIGINAL ARTICLE

Microbiota network and mathematic microbe mutualism in colostrum and mature milk collected in two different geographic areas: Italy versus Burundi

Lorenzo Drago^{1,2}, Marco Toscano¹ Roberta and Diego G Peroni^{5,6}

> Bacterial relations changed within the same population, underlying that colostrum and mature milk are different not only for protein and fat content but also for the microbiota composition.

> We believe some bacterial genera are essential in the first phase of lactation, and for this reason, they have a pivotal role in colostrum, while other microorganisms are fundamental in the long-term nutrition of newborns

Bacterial distribution in each type of milk sample: (a) Italian colostrum; (b) Italian mature milk; (c) Burundian colostrum; Purundian mature milk



Colostrum in ..



Microbiome and its Impact on Gastrointestinal Atopy. Muir, Allergy 2016

Commensal bacteria and their role in the development of tolerance.

Commensal colonization decreases IgE-basophil axis and increases TLR stimulation thus promoting tolerance.

Dysbiosis and ineffective TLR signaling leads to enhanced Th2 response and IgEmediated disease.



Transforming Life: A Broad View of the Developmental Origins of Health and Disease Concept from an Ecological Justice Perspective. S. Prescott, Int. J. Environ. Res. Public Health 2016, 13, 1075

Dysbiosis is a term that translates as "difficult living" or "life in distress"; given neighborhood grey space, massive health disparities, matters of economic and environmental injustices, biodiversity losses, climate change, rapid urbanization and other threats to ecosystems, it has been argued that dysbiosis can apply at the individual, neighborhood and global level.



Transforming Life: A Broad View of the Developmental Origins of Health and Disease Concept from an Ecological Justice Perspective. S. Prescott, Int. J. Environ. Res. Public Health 2016, 13, 1075

The drivers of microbial dysbiosis (e.g., **westernized/ultraprocessed diet**, **stress**, **alcohol**, **tobacco**, **circadian disruptions**, **antibiotic use**, et al.) are slanted toward the SES disadvantaged in developed nations, and increasingly so in developing nations.

The presence of grey space (an environment maintained by marketing forces and absence of policy that could otherwise transform opportunity for health) accompanies disadvantage and contributes to what has been referred to as "dysbiotic drift". Probiotics are "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host"

Thus, viability is considered to be a fundamental requirement for probiotics

Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506





In humans, by far, the most commonly used probiotics are bacteria from the genus Lactobacillus or Bifidobacterium, and a yeast, Saccharomyces boulardii.

However, novel probiotics are an area of current investigation.

Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506

| Table 3 Effects of probiotics | in children | | |
|---|---|--|--------|
| Condition | Effect of probiotics as a group | Examples of probiotics with documented or promising efficacy | Ref |
| Acute gastroenteritis (treatment) | Approximately 1-day reduction in the duration of diarrhoea | ESPGHAN Strong recommendation ► Lactobacillus GG ► S. boulardii Weak recommendation ► L. reuteri DSM 17938 | а С |
| Antibiotic-associated diarrhoea (prevention) | Reduced risk | Lactobacillus GG S. boulardii | 6 7 |
| Nosocomial diarrhoea (prevention) | Reduced risk | ► Lactobacillus GG | 10 |
| Infections in children attending day care centres (prevention) | Reduced risk | Promising ► Lactobacillus GG ► L. reuteri DSM 17938 | 14 19 |
| Allergy (prevention) | Reduced risk of eczema | WAO suggests the use of probiotics in select high-risk populations to reduce the risk of eczema; however, there is no clear indication regarding which probiotic(s) to use | 25 20 |
| NEC (prevention) | Reduced risk of NEC and mortality in infants who were born <1500 g | No clear indications from scientific societies regarding which probiotic strain(s) should be recommended | 27 |
| H. pylori infection | Reduced risk of side effects and increased eradication rate | No clear indications which strain(s) to use Promising ► 5. boulardii | 32 3 |
| Infantile colic (management) | Reduced crying time | L. reuteri DSM 17938 (documented in breastfed infants) | 35-4 |
| Abdominal pain- related functional gastrointestinal disorders | Certain probiotics reduced intensity of pain (especially in patients with irritable bowel syndrome) | More studies are needed to identify beneficial strains. Promising Lactobacillus GG VSL#3 | 424 |
| Induction of remission in ulcerative colitis | Limited evidence suggests that probiotics added to standard therapy may provide modest benefits | ESPGHAN/ECCO F. coli Nissle 1917 VSL#3 | 20 |
| Induction of remission in Crohn's disease | Insufficient evidence | ECCO/ESPGHAN: not recommended | 54 |
| Functional constipation | Until more data are available, the use of probiotics should be considered investigational | ESPGHAN/NASPGHAN: not recommended | 44 |

What are the indications for using probiotics in children? Hania Szajewska. Arch Dis Child 2015



based clinical practice guidelines, developed by scientific societies.

Probiotici e Allergopatie

Diego Peroni

Università di Pisa



FIRENZE 6/9 APRILE 2017 | WWW.SIAAIC2017.ORG

Microbioma, disbiosi e malattia

Probiotici e Allergia

Conclusioni





de Silva D. **EAACI** Food Allergy and Anaphylaxis Guidelines Group. Primary prevention of food allergy in children and adults: systematic review. Allergy 2014;69:581.

Muraro A. EAACI Food Allergy and Anaphylaxis Guidelines Group. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy 2014;69:590

> There is no evidence to support the use of probiotics (also prebiotics) for food allergy prevention

Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials. Cuello-Garcia, JACI, 2015;136:952

| | | | | Anticipate | d absolute effects | |
|---|----------------------------------|---|---------------------------------|--|--|---------|
| Outcomes | No. of participants (studies) | Quality of evidence (GRADE) | Relative effect, RR (95% CI) | Risk with no probiotics | Risk difference with probiotics | |
| Eczema, follow-up: range, 6-24 mo | 2657 (10 RCTs)* | ●○○○ Very low†‡§ | 0.80 (0.64-0.93) | Stud | y population | |
| | | | | 289 per 1000 | 58 fewer per 1000 (104 fewer to 20 fewer) | |
| Atopic eczema, follow-up: range, 6-36 mo | 2218 (7 RCTs)* | ●○○○ Very lowद | 0.62 (0.51-0.76) | Stud | y population | |
| | | | | 198 per 1000 | 73 fewer per 1000 | |
| Asthma/wheezing, follow-up: range, 6-36 mo | 1733 (6 RCTs) | Key messag | es | | | |
| | | Probiot | tics given | to pregnant | women, breast-f | feeding |
| Food allergy, follow-up: range, 6-24 mo | 295 (2 RCTs) | mother | rs, and/or | infants reduce | d the risk of ecze | ema in |
| | | infants | • | | | |
| Allergic rhinitis, follow-up: range, 12-36 mo | 1465 (4 RCTs) | • Curren otics p | tly availab | le evidence doe development of | s not indicate that f other allergies. | probi- |
| | | | | | | |
| Any allergy, follow-up: range, 6-24 mo | 1152 (3 RCTs) | Design identifi | of future : ed regardi | studies should | consider the weak bias and indirect | ness of |
| | | the ord | dan aa | | Shus und maneet | |
| Adverse events, follow-up: range, 6-36 mo | 642 (2 RCTs) | Very low \$ †† | aence. | | 1.5.5 | |
| | | | | 196 per 1000 | 6 more per 1000 | |
| | | | | | (59 fewer to 102 more) | |
| Nutritional status assessed with growth and weight, follow-up: range, 3-36 mo | 454 (1 RCT) | ●○○○ Very low§∥†† | Not estimable | Mean nutritional status: 0 infants only in the control group | SMD, 0 higher (0.18 lower to 0.18 higher) | |

World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): probiotics. Fiocchi A, Pawankar R, Cuello-Garcia C, et al. World Allergy Organ J 2015;8:4.

✓ A systematic review.

✓29 publications

✓12 various
 probiotics single or
 in combination

✓ Except for LGG none in more than one trial



World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): probiotics.

Fiocchi A, Pawankar R, Cuello-Garcia C, et al. World Allergy Organ J 2015;8:4.

✓ A system review.

√29 pub

✓11 pro in co

✓ Ex none one tr In line with the EAACI, the WAO experts agreed that probiotic supplementation cannot be recommended for reducing the risk of allergy in children.

However, the WAO considered that there is a likely net benefit from using probiotics for preventing eczema...

norners (CI 0.47-0.69) Infants CI 0.68-0.94

ducing

with

World Allergy Organization-McMast

WAO suggests: Fiocchi A, Paw "a) using probiotics in pregnant women at high risk for having an allergic child; ✓ A sy b) using probiotics in women who reviei breastfeed infants at √29 pt high risk of developing allergy; and c) using probiotics in √12 va probiot infants at high risk of developing in combin allergy. venting All recommendations n 20 were conditional and supported Infants by a very low quality of hers CI 0.68-0.94 evidence. 0.47-0.69)

se

Recommendations on probiotics in allergy prevention should not be based on pooling data from different strains Hania Szajewska. JACI 2015

One important limitation of the WAO guidelines is the lack of answers to the most important practical questions.

Which probiotic(s) should be used to reduce the risk of eczema?

When should one start the administration of probiotics with proven efficacy?

When should one stop?

What is the dose of an effective probiotic?

Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis Pelucchi C, Epidemiology 2012; 23:402

✓ meta-analysis of randomized controlled trials to investigate whether probiotic use during pregnancy and early life decreases the incidence of atopic dermatitis and immunoglobulin E (IgE)associated atopic dermatitis in infants and young children.

| Study | Year | Treatment No./Total | Placebo No./Total | | RR (95% CI) | Weight % |
|------------------|-----------|------------------------|----------------------|---------------|------------------|-------------|
| Kalliomaki | 2001 | 15/64 | 31/68 | | 0.51 (0.32-0.84) | 4.82 |
| Rauta∨a | 2006 | 4/32 | 8/40 | | 0.63 (0.21-1.89) | 0.93 |
| Abrahamsson | 2007 | 34/95 | 32/93 | ÷. | 1.04 (0.70-1.53) | 7.34 |
| Kukkonen | 2007 | 120/461 | 150/464 | | 0.81 (0.66-0.99) | 27.29 |
| Taylor | 2007 | 38/88 | 34/87 | | 1.10 (0.77-1.58) | 8.68 |
| Корр | 2008 | 19/50 | 14/44 | ÷ = | 1.19 (0.68-2.09) | 3.56 |
| Wickens | 2008 | 57/290 | 40/146 | | 0.72 (0.50-1.02) | 8.83 |
| Kim | 2009 | 12/33 | 22/35 | | 0.58 (0.34-0.97) | 4.08 |
| Niers | 2009 | 27/50 | 33/48 | - \$ - | 0.79 (0.57-1.08) | 10.98 |
| Soh | 2009 | 27/124 | 30/121 | _ | 0.88 (0.56-1.39) | 5.43 |
| West | 2009 | 9/84 | 19/87 | | 0.49 (0.24-1.02) | 2.14 |
| Dotterud | 2010 | 29/138 | 48/140 | - B + | 0.61 (0.41-0.91) | 7.06 |
| Boyle | 2011 | 35/108 | 43/102 | -++- | 0.77 (0.54-1.10) | 8.86 |
| Overall (I-squar | ed = 24.0 | 9%, p = 0.201) | | \$ | 0.79 (0.71-0.88) | 100.00 |

Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis Pelucchi C, Epidemiology 2012; 23:402

meta-analysis of randomized controlled trials to investigate whether probiotic use during pregnancy and early life decreases the incidence of atopic dermatitis and immunoglobulin E (IgE)associated atopic dermatitis in infants and young children. RR for IgE associated atopic dermatitis



Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis.

Zuccotti G and *Task Force on Probiotics of the Italian Society of Neonatology, Allergy 2015; 70:1376



Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis.

Zuccotti G and *Task Force on Probiotics of the Italian Society of Neonatology, Allergy 2015; 70:1376

 systematic review and meta-analysi

 ✓ 17 studies reporting de from 4755 children (2) in the probiotic group) No significant difference in terms of prevention of asthma (RR 0.99 [95% CI: 0.77-1.27], P = 0.95), wheezing (RR 1.02 [95% CI: 0.89-1.17], P = 0.76) or rhinoconjunctivitis (RR 0.91 [95% CI: 0.67-1.23], P = 0.53) was documented

> Overall probiotics (CI 0.69-0.89)

Mixture of probiotics (CI 0.43-0.68)

What are the indications for using probiotics in children? Hania Szajewska. Arch Dis Child 2015

One imp a

Whi

When effic

When Sn.

Probiotics as a group reduce the risk of eczema. However, it would be premature to support the routine use of probiotics for preventing eczema. Data regarding which probiotic products should be administered, at what dosages and the most effective dosing schedule are needed

What is the dose of an effect.

Changing of Fecal Flora and Clinical Effect of L. salivarius LSO1 in Adults With Atopic Dermatitis.

Drago L, J Clin Gastroenterol 2012;46:556.



Probiotics Reduce Gut Microbial Translocation and Improve Adult Atopic Dermatitis. Iemoli, J Clin Gastroenterol 2012;46:533

48 pts were enrolled (randomization ratio 2:1)

treated with a combination (Lactobacillus salivarius and Bifidobacterium breve or placebo (maltodextrin) for 12 weeks.

Clinical efficacy was assessed from baseline by changes in the SCORAD index and DLQ index improvement. Regulatory T cells: TGF-b-secreting and IL-10-secreting regulatory T cells



Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials Kim Ann Allergy 2014;113:217

25 randomized
 controlled trials
 (n = 1,599).

Significant differences in SCORAD values favoring probiotics over the control were observed:

- overall (mean - 4.51), -in children 1 to 18 yrs old (- 5.74), -in adults (- 8.26). Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials Kim Ann Allergy 2014;113:217

However, the effectiveness of probiotics in infants (< 1 yr old) with AD was not proved. Significant differences in SCORAD values favoring probiotics over the control were observed:

- overall (mean - 4.51), -in children 1 to 18 yrs old (- 5.74), -in adults (- 8.26). Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials Kim Ann Allergy 2014;113:217

The overall result of this meta-analysis suggests that probiotics could be an option for the treatment of AD, especially for moderate to severe AD in children and adults.

Significant differences in SCORAD values favoring probiotics over the control were observed:

- overall (mean - 4.51), -in children 1 to 18 yrs old (- 5.74), -in adults (- 8.26).

Administration of a probiotic with peanut oral immunotherapy: A randomized trial Tang MLK, J Allergy Clin Immunol 2015; 135:737-44

- Lactobacillus rhamnosus
 CGMCC 1.3724 and peanut
 OIT (probiotic and peanut
 oral immunotherapy) or
 placebo.
- ✓ 62 children (1-10 years) with peanut allergy.
- Sustained unresponsiveness
 2 to 5 weeks after
 discontinuation of
 treatment.

% children achieving sustained unresponsiveness 2 to 5 weeks after discontinuation of treatment 90 -80 82.1% 70 p<0.001 60 50 40 30 20 10 3.6% 0 Placebo Probiotic +OIT

Probiotici e Allergopatie

Diego Peroni

Università di Pisa

Microbioma, disbiosi e malattia

Probiotici e Allergia

Conclusioni





FIRENZE 6/9 APRILE 2017 | WWW.SIAAIC2017.ORG





Signals from the gut microbiota to distant organs in physiology and disease. Schroeder BO, Nature Med, 2016: 22:1079

Gut microbiota convert environmental signals and dietary molecules into signaling metabolites to communicate with the host.

At the top of the figure are indicated factors that can alter the composition of the gut microbiota.

The gut microbiota converts these inputs into metabolites, which can signal to different organs and tissues in the host, as indicated below.



How gut microbes talk to organs: The role of endocrine and nervous routes. Cani PD, Molecular Metabolism, 2016; 5:743



Secretion of such hormones control appetite, gut barrier, and glucose homeostasis (e.g., insulin sensitivity) via direct interactions with organs but also through nervous routes. Similar to what is observed in the brain, different neurotransmitters or molecules (produced by intestinal microbes), such as nitric oxide (NO) as well as g-aminobutyric acid (GABA), act through the enteric nervous system (ENS). Secondary messengers, including NO, serotonin, acetylcholine (Ach) or vasoactive intestinal polypeptide (VIP) release, are involved in the gut to peripheral organ and brain communication, leading to the control of different behaviors (e.g., food intake, anxiety, stress) Signals from the gut microbiota to distant organs in physiology and disease. Schroeder BO, Nature Med,

2016: 22:1079

Obesity in humans has been associated with reduced microbial diversity as compared to lean controls.

However, it is at present unknown whether the reduced **microbial diversity** contributes to obesity or merely reflects the obesogenic lifestyle and dietary habits, because **diets** without fiber dramatically reduce microbial diversity and the capacity to metabolize complex carbohydrates



Signals from the gut microbiota to distant organs in physiology and disease. Schroeder BO, Nature Med,

2016: 22:1079

Obesity in humans has been associated with reduced microbial diversity as compared to lean controls.

However, it is at present unknown whether the

The gut microbiota actively communicates with the host, similarly to other human organs, and we are only just beginning to decipher their signals and their relevance for human health and disease.



| Table 3 Effects of probiotics | in children | |
|---|---|--|
| Condition | Effect of probiotics as a group | Examples of probiotics with documented or promising efficacy |
| Acute gastroenteritis (treatment) | Approximately 1-day reduction in the duration of diarrhoea | ESPGHAN Strong recommendation ► Lactobacillus GG ► S. boulardii Weak recommendation ► L. reuteri DSM 17938 |
| Antibiotic-associated diarrhoea (prevention) | Reduced risk | Lactobacillus GG S. boulardii |
| Nosocomial diarrhoea (prevention) | Reduced risk | Lactobacillus GG |
| Infections in children attending day care centres (prevention) | Reduced risk | Promising Lactobacillus GG L. reuteri DSM 17938 |
| Allergy (prevention) | Reduced risk of eczema | WAO suggests the use of probiotics in select high-risk populations to reduce the risk of eczema; however, there is no clear indication regarding which probiotic(s) to use |
| NEC (prevention) | Reduced risk of NEC and mortality in infants who were born <1500 g | No clear indications from scientific societies regarding which probiotic strain(s) should be recommended |
| H. pylori infection | Reduced risk of side effects and increased eradication rate | No clear indications which strain(s) to use Promising S. <i>boulardii</i> |
| Infantile colic (management) | Reduced crying time | L. reuteri DSM 17938 (documented in breastfed infants) |
| Abdominal pain- related functional gastrointestinal disorders | Certain probiotics reduced intensity of pain (especially in patients with irritable bowel syndrome) | More studies are needed to identify beneficial strains. Promising Lactobacillus GG VSL#3 |
| Induction of remission in ulcerative colitis | Limited evidence suggests that probiotics added to standard therapy may provide modest benefits | ESPGHAN/ECCO E. coli Nissle 1917 VSL#3 |
| Induction of remission in Crohn's disease | Insufficient evidence | ECCO/ESPGHAN: not recommended |
| Functional constipation | Until more data are available, the use of probiotics should be considered investigational | ESPGHAN/NASPGHAN: not recommended |

Primary prevention of allergy - Will it soon become a reality? Van Bever PAI 2016, 27:6



Many life style risk factors for NCDs have both immune and metabolic effects.



These are also the logical targets to prevention inflammation and metabolic dysregulation.

Prescott S, Allergol Int. 2014;63(1):11-20